CN1568991A - Desloratadine diapersible tablet and its preparation method - Google Patents
Desloratadine diapersible tablet and its preparation method Download PDFInfo
- Publication number
- CN1568991A CN1568991A CN 03141743 CN03141743A CN1568991A CN 1568991 A CN1568991 A CN 1568991A CN 03141743 CN03141743 CN 03141743 CN 03141743 A CN03141743 A CN 03141743A CN 1568991 A CN1568991 A CN 1568991A
- Authority
- CN
- China
- Prior art keywords
- desloratadine
- dispersible tablet
- coating
- tablet according
- acrylic resin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960001271 desloratadine Drugs 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 8
- 239000003463 adsorbent Substances 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 239000000314 lubricant Substances 0.000 claims abstract description 6
- 239000011248 coating agent Substances 0.000 claims description 23
- 238000000576 coating method Methods 0.000 claims description 23
- 239000007919 dispersible tablet Substances 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000004531 microgranule Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000004925 Acrylic resin Substances 0.000 claims description 8
- 229920000178 Acrylic resin Polymers 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- -1 oven dry Substances 0.000 claims description 3
- 235000019890 Amylum Nutrition 0.000 claims description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229950005770 hyprolose Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000002304 perfume Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000005303 weighing Methods 0.000 description 5
- 239000000739 antihistaminic agent Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940124623 antihistamine drug Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 210000003912 basophilic leucocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical class C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to desloratadine diapersible tablet and its preparation method, which comprises desloratadine diapersible, dressing material, adsorbent, crumbling agent, bulking agent, water-soluble excipient, perfume compound, sweetener, and lubricating agent.
Description
Technical field
The present invention relates to a kind of dosage form of antihistamine drug Desloratadine, relate in particular to Desloratadine dispersible tablet and preparation method thereof.
Background technology
Desloratadine is the long-acting tricyclic antidepressants antihistaminic of non-sedating, is the active metabolite of loratadine, can be by optionally blocking periphery H
1Receptor suppresses the release that various anaphylaxis cause scorching chemical mediator, as: suppress mastocyte and basophilic leukocyte and discharge histamine, prostaglandin, interleukin etc., alleviate allergic rhinitis or the urticarial related symptoms of chronic idiopathic.At present, Desloratadine is capsule or conventional tablet all generally, and water is swallowed, because these dosage form volumes are bigger, are not suitable for more weak old man of swallow and child and take, and also has taking of under special environment (as hydropenia) patient.
Summary of the invention
The antihistamine drug Desloratadine dispersible tablet that the object of the present invention is to provide the more weak patient of a kind of suitable swallow to take.
Another object of the present invention has provided a kind of preparation method of antihistamine drug Desloratadine dispersible tablet.
A kind of Desloratadine dispersible tablet, comprise Desloratadine crude drug and coating material and adjuvant composition, adjuvant comprises disintegrating agent, filler, water soluble excipient and adsorbent, wherein contain 0.1%～10% Desloratadine in every Desloratadine dispersible tablet, 25%～50% adsorbent, 5%～15% disintegrating agent, 10%～30% filler, 25%～50% water soluble excipient, 0.5%～3% essence, 0.5%～3% sweeting agent, 0.5%～1.5% lubricant; Disintegrating agent is a crospolyvinylpyrrolidone, one or more mixing in cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, the carboxymethyl starch sodium; Filler is microcrystalline Cellulose, pregelatinized Starch, amylum pregelatinisatum, hypromellose, sedimentation silicon dioxide; Water soluble excipient is the solubility polyhydric alcohol with adhesion characteristic; Adsorbent is crospolyvinylpyrrolidone, microcrystalline Cellulose, starch, calcium hydrogen phosphate, sedimentation silicon dioxide; Coating material is Eudragit E 100, acrylic resin NE30D, II acrylic resin, III acrylic resin, IV acrylic resin, hypromellose, hyprolose, ethyl cellulose; Can also contain essence, sweeting agent and lubricant in the adjuvant.
The preparation method of a kind of Desloratadine dispersible tablet of the present invention comprises the steps:
1), Desloratadine raw material and coating material put into the boiling granulating machine carry out coating, obtain the Desloratadine microgranule of coating;
(2), Desloratadine microgranule and adjuvant mix homogeneously that coating is good, the system soft material, oven dry, granulate, tabletting are promptly.
A kind of Desloratadine dispersible tablet of the present invention, compare with dosage form in the past, owing to added disintegrating agent, can be in the oral cavity disintegrate and dissolving fast, no grittiness, swallow into stomach with saliva easily, take (as hydropenia) so relatively be fit to more weak old man of the power of swallowing and child or the patient under special environment, and taste is also better.
The specific embodiment
The invention will be further described below in conjunction with embodiment, but the present invention is not subjected to the restriction of embodiment.
Embodiment 1: the raw material coating of Desloratadine
Take by weighing raw material: Desloratadine 250g ethyl cellulose 25g
Isopropyl alcohol 150ml ethanol 850ml
Above-mentioned raw materials is placed the boiling granulating machine, carry out the raw material coating, obtain coating Desloratadine microgranule.
Embodiment 2: the raw material coating of Desloratadine
Take by weighing raw material: Desloratadine 250g EUDRAGITE100 25g
Ethanol 1000ml
Above-mentioned raw materials is placed the boiling granulating machine, carry out the raw material coating, obtain coating Desloratadine microgranule.
Embodiment 3: the preparation of Desloratadine dispersible tablet
1, take by weighing raw material by following prescription:
Coating Desloratadine microgranule 5g (in Desloratadine)
Starch 54g calcium hydrogen phosphate 16g
30 POVIDONE K 30 BP/USP 30 2g carboxymethylstach sodium 54g
Micropowder silica gel 1g magnesium stearate 1g
Make 1000
2, increase progressively dilution method with coating Desloratadine microgranule, calcium hydrogen phosphate, shallow lake with equivalent
Powder and carboxymethylstach sodium mix homogeneously;
3,, mixture is made the wet granular of even soft material with 18 mesh sieves with 10% 30 POVIDONE K 30 BP/USP 30 (70% alcoholic solution) preparation binding agent;
4, wet granular is used 18 mesh sieve granulate then in 55 ℃ of oven dry, adds other adjuvants, mixing, and with moderate pressure compressed tablets, every heavily about 0.1g.
Embodiment 4: in order to improve taste, can also add essence, sweeting agent and lubricant in dispersible tablet.
1, take by weighing raw material by following prescription:
Coating Desloratadine microgranule 5g (in Desloratadine)
Polyvinylpolypyrrolidone 8.0g microcrystalline Cellulose 37.0g
Low-substituted hydroxypropyl cellulose 5.0g mannitol 40.0g
Orange flavor 1.0g aspartame 3.0g
Micropowder silica gel 1.25g magnesium stearate 1.0g
Ethanol is an amount of
Make 1000
2, get the Desloratadine microgranule of coating, take by weighing polyvinylpolypyrrolidone, microcrystalline Cellulose, low-substituted hydroxypropyl cellulose, mannitol, magnesium stearate, orange flavor, aspartame and the micropowder silica gel of formula ratio, mix homogeneously;
3, system soft material, oven dry, granulate, tabletting.
A kind of Desloratadine dispersible tablet of the present invention, can be in the oral cavity disintegrate fast, and dissolve, no grittiness is swallowed into stomach with saliva easily.
Claims (8)
1, a kind of Desloratadine dispersible tablet, comprise Desloratadine crude drug and coating material and adjuvant composition, adjuvant comprises disintegrating agent, filler, water soluble excipient and adsorbent, contain 0.1%～10% Desloratadine in it is characterized in that every, coating material 5%～20%, 25%～50% adsorbent, 5%～15% disintegrating agent, 10%～30% filler, 25%～50% water soluble excipient, 0.5%～3% essence, 0.5%～3% sweeting agent, 0.5%～1.5% lubricant.
2, Desloratadine dispersible tablet according to claim 1 is characterized in that disintegrating agent is a crospolyvinylpyrrolidone, one or more mixing in cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, the carboxymethyl starch sodium.
3, Desloratadine dispersible tablet according to claim 1 is characterized in that filler is microcrystalline Cellulose, pregelatinized Starch, amylum pregelatinisatum, hypromellose, sedimentation silicon dioxide.
4, Desloratadine dispersible tablet according to claim 1 is characterized in that water soluble excipient is the solubility polyhydric alcohol with adhesion characteristic.
5, Desloratadine dispersible tablet according to claim 1 is characterized in that adsorbent is crospolyvinylpyrrolidone, microcrystalline Cellulose, starch, calcium hydrogen phosphate, sedimentation silicon dioxide
6, Desloratadine dispersible tablet according to claim 1 is characterized in that described coating material is Eudragit E 100, acrylic resin NE30D, II acrylic resin, III acrylic resin, IV acrylic resin, hypromellose, hyprolose, ethyl cellulose.
7, Desloratadine dispersible tablet according to claim 1 is characterized in that containing in the adjuvant essence, sweeting agent and lubricant.
8, plant the preparation method of Desloratadine dispersible tablet, it is characterized in that comprising the steps:
(1), Desloratadine raw material and coating material put into the boiling granulating machine carry out coating, obtain the Desloratadine microgranule of coating;
(2), Desloratadine microgranule and adjuvant mix homogeneously that coating is good, the system soft material, oven dry, granulate, tabletting are promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031417434A CN100563654C (en) | 2003-07-22 | 2003-07-22 | A kind of Desloratadine dispersible tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031417434A CN100563654C (en) | 2003-07-22 | 2003-07-22 | A kind of Desloratadine dispersible tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1568991A true CN1568991A (en) | 2005-01-26 |
| CN100563654C CN100563654C (en) | 2009-12-02 |
Family
ID=34471044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031417434A Expired - Lifetime CN100563654C (en) | 2003-07-22 | 2003-07-22 | A kind of Desloratadine dispersible tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100563654C (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006008512A3 (en) * | 2004-07-16 | 2006-08-03 | Cipla Ltd | Anti-histaminic composition |
| CN102048682B (en) * | 2009-10-31 | 2012-09-12 | 鲁南制药集团股份有限公司 | Loratadine cream and application thereof |
| CN102940617A (en) * | 2012-11-21 | 2013-02-27 | 北京润德康医药技术有限公司 | Desloratadine oral dispersible film |
| CN104523644A (en) * | 2015-01-27 | 2015-04-22 | 严白双 | Rapidly-dissolved loratadine tablets and preparation process thereof |
| CN106667922A (en) * | 2017-02-16 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | Solid desloratadine dispersion preparation and preparation method thereof |
| CN106822047A (en) * | 2017-02-15 | 2017-06-13 | 佛山市腾瑞医药科技有限公司 | A kind of microporous barrier controlled release coat Desloratadine micropill and preparation method thereof |
| CN106822025A (en) * | 2017-01-02 | 2017-06-13 | 佛山市腾瑞医药科技有限公司 | A kind of Desloratadine soft capsule preparation and its preparation technology |
| CN106860423A (en) * | 2017-02-15 | 2017-06-20 | 佛山市腾瑞医药科技有限公司 | A kind of Desloratadine fast release micropill preparation, preparation method |
| CN106880609A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of Suo Feibuwei dispersible tablets and preparation method thereof |
| CN107095853A (en) * | 2017-04-01 | 2017-08-29 | 重庆康刻尔制药有限公司 | A kind of oral disnitegration tablet disintegrant combination and its application method |
| CN108403649A (en) * | 2018-04-10 | 2018-08-17 | 常州方圆制药有限公司 | A kind of Desloratadine piece and preparation method thereof |
| CN109925289A (en) * | 2019-04-11 | 2019-06-25 | 海南普利制药股份有限公司 | Desloratadine dispersible tablet |
-
2003
- 2003-07-22 CN CNB031417434A patent/CN100563654C/en not_active Expired - Lifetime
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006008512A3 (en) * | 2004-07-16 | 2006-08-03 | Cipla Ltd | Anti-histaminic composition |
| CN102048682B (en) * | 2009-10-31 | 2012-09-12 | 鲁南制药集团股份有限公司 | Loratadine cream and application thereof |
| CN102940617A (en) * | 2012-11-21 | 2013-02-27 | 北京润德康医药技术有限公司 | Desloratadine oral dispersible film |
| CN104523644B (en) * | 2015-01-27 | 2017-06-20 | 江苏联环药业股份有限公司 | The Loratadine tablet and its preparation technology of a kind of Fast Stripping |
| CN104523644A (en) * | 2015-01-27 | 2015-04-22 | 严白双 | Rapidly-dissolved loratadine tablets and preparation process thereof |
| CN106880609A (en) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | A kind of Suo Feibuwei dispersible tablets and preparation method thereof |
| CN106822025A (en) * | 2017-01-02 | 2017-06-13 | 佛山市腾瑞医药科技有限公司 | A kind of Desloratadine soft capsule preparation and its preparation technology |
| CN106860423A (en) * | 2017-02-15 | 2017-06-20 | 佛山市腾瑞医药科技有限公司 | A kind of Desloratadine fast release micropill preparation, preparation method |
| CN106822047A (en) * | 2017-02-15 | 2017-06-13 | 佛山市腾瑞医药科技有限公司 | A kind of microporous barrier controlled release coat Desloratadine micropill and preparation method thereof |
| CN106667922A (en) * | 2017-02-16 | 2017-05-17 | 佛山市腾瑞医药科技有限公司 | Solid desloratadine dispersion preparation and preparation method thereof |
| CN107095853A (en) * | 2017-04-01 | 2017-08-29 | 重庆康刻尔制药有限公司 | A kind of oral disnitegration tablet disintegrant combination and its application method |
| CN108403649A (en) * | 2018-04-10 | 2018-08-17 | 常州方圆制药有限公司 | A kind of Desloratadine piece and preparation method thereof |
| CN109925289A (en) * | 2019-04-11 | 2019-06-25 | 海南普利制药股份有限公司 | Desloratadine dispersible tablet |
| CN109925289B (en) * | 2019-04-11 | 2021-05-25 | 海南普利制药股份有限公司 | Desloratadine dispersible tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100563654C (en) | 2009-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1267106C (en) | Simethicone/anhydrous calcium phosphate compositions | |
| RO118563B1 (en) | Dosed oral composition with instantaneous decomposition, and process for obtaining the same | |
| WO1998022105A1 (en) | Tabletted preparation | |
| CN1339972A (en) | Tablets quickly disintegrated in the oral cavity | |
| CN1568991A (en) | Desloratadine diapersible tablet and its preparation method | |
| CN1482903A (en) | Nateglinide-containing preparation | |
| EP1843754A1 (en) | New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance | |
| HUT74477A (en) | Film coated tablet of paracetamol and domperidone | |
| EP2197428A1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
| JP6623753B2 (en) | Orally disintegrating tablets containing lanthanum carbonate | |
| EP2012754B1 (en) | Oral rapid release pharmaceutical formulation for esomeprazole | |
| CN100339081C (en) | Oral loratadine disintegrating tablet and its prepn | |
| KR101433428B1 (en) | Multi layer pharmaceutical tablet with improved stability comprising sulglycotide and h２ antagonists and preparation method thereof | |
| CN1903183A (en) | Dispersion tablets of telbivudine and its prepn. method | |
| EP1635794A2 (en) | Nitrofurantoin controlled release dosage form | |
| CN1247195C (en) | Silibinin oral disintegration tablet and its preparing method | |
| CN1582927A (en) | Oral disintegrants of nimodipine and their preparation | |
| CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
| CN1762354A (en) | Stable pharmaceutical composition containing calcium blocker | |
| JP2010001242A (en) | Rebamipide solid preparation, and method for producing the same | |
| JP2004352633A (en) | Magnesium oxide tablet | |
| CN1689639A (en) | Tannalbin rapid disintegration preparation and preparing method thereof | |
| JP6037687B2 (en) | Orally disintegrating tablets containing glimepiride | |
| CN1557309A (en) | Amlodipine dispersion tablet and its preparation method | |
| CN1245163C (en) | Puerarin dispersing tablet composition and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan Poly Pharm Co.,Ltd. Assignor: Fan Minhua Contract record no.: 2010330000861 Denomination of invention: Desloratadine diapersible tablet and its preparation method Granted publication date: 20091202 License type: Exclusive License Open date: 20050126 Record date: 20100513 |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG RUIDA PHARMACEUTICAL CO., LTD. HANGZHOU S Owner name: HAINAN POLY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: FAN MINHUA Effective date: 20100707 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310004 HOUSE 5, BUILDING 9, NO.167, HUANCHENG NORTH ROAD, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 571127 GUILINYANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, MEILAN DISTRICT, HAIKOU CITY, HAINAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100707 Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Co-patentee after: Zhejiang Ruida Pharmaceutical Co.,Ltd. Patentee after: Hainan Poly Pharm Co.,Ltd. Co-patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 5, No. 9, building 167, building 310004, Ring North Road, Hangzhou, Zhejiang Patentee before: Fan Minhua |
|
| CI01 | Publication of corrected invention patent application |
Correction item: Patentee Correct: Zhejiang Ruida Pharm Co.,Ltd. False: Zhejiang Ruida Pharmaceutical Co.,Ltd. Number: 33 Volume: 26 |
|
| CI03 | Correction of invention patent |
Correction item: Patentee Correct: Zhejiang Ruida Pharm Co.,Ltd. False: Zhejiang Ruida Pharmaceutical Co.,Ltd. Number: 33 Page: The title page Volume: 26 |
|
| C56 | Change in the name or address of the patentee |
Owner name: HAINAN PLOY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: HAINAN PULIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee after: HAINAN POLY PHARM. Co.,Ltd. Patentee after: ZHEJIANG POLY PHARMACEUTICAL Co.,Ltd. Patentee after: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. Address before: 571127 Guilin economic and Technological Development Zone, Meilan District, Hainan, Haikou Patentee before: Hainan Poly Pharm Co.,Ltd. Patentee before: Zhejiang Ruida Pharm Co.,Ltd. Patentee before: HANGZHOU SHARPLY PHARM R&D INSTIT. Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20091202 |